Introduction
Prostate cancer is the most commonly diagnosed cancer and the third-leading cause of cancer deaths in men.
1 Although approximately 75% of these patients will be cured by surgery or radiation when cancer remains within the prostate, the remainder will inevitably progress to a state of metastatic prostate cancer.
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Androgen deprivation therapy or other combination therapy, through lowering serum testosterone or competitively blocking the binding of androgens to the androgen receptor (AR), are initially effective in 90% of patients at this stage. 3 Nevertheless, the vast majority of these patients will eventually develop metastatic castration resistant prostate cancer (CRPC) aer long term treatments. [4] [5] [6] Recent research efforts have indicated that CRPC growth is driven by AR signaling as well. 7 Furthermore, many possible mechanisms inuencing AR signaling have been suggested for the acquired resistance, among which AR mutations, androgen synthesis by prostate cancer cells, and over-expression of AR or AR co-activators have been found to directly or indirectly render AR more sensitive to low androgen concentrations or sometimes turn antagonist responses to agonistic. Enzalutamide (ENT) was approved by FDA in 2012 for the treatment of CRPC. Unlike the rst-generation AR inhibitors, such as utamide, nilutamide, and bicalutamide ( Fig. 1) , ENT not only binds to AR, but also reduces nuclear translocation of AR and impairs AR binding to DNA. 9 In addition, further studies suggested that ENT possesses a higher binding affinity of AR than the rst-generation AR inhibitors. Clinical studies also demonstrated unequivocally its survival benet in men with CRPC. 10, 11 Despite its success, the duration of response in patients is still limited. Recently, AR with a specic mutation (F876L) was identied to confer resistance to ENT. 12 This disappointing outlook suggests that better compounds with novel structure motif need to be developed urgently. Replacement of amide group by other isosteres is a common practice in medicinal chemistry effort. Black and his colleagues from Merck reported to use triuoroethylamine group as the isostere of amide in their searching of novel cathepsin K inhibitors. 13 Aer replacement of amide with triuoroethyl-amine, the potency and selectivity were improved, also the new function group are stable for P1-P2 cleavage that was observed for other amide inhibitors. Considering the major metabolic path way of ENT is through N-demthylation and amide hydrolysis, 14 ,15 a series of isosteres analogs bearing triuoroethyl-amine or triuoroethanol were prepared as novel AR inhibitors. At the same time, C-ring was also optimized for potentially improvement of drug resistance (Fig. 2) . Here we report our progress and also the in vivo and in vitro data of compound 13b which is dose-dependently inhibiting expression of prostatespecic antigen and has anti-tumor activity at oral administration dose of 15 mg kg À1 once daily.
Results and discussion

Chemistry
Synthetic routes of evaluated compounds 13a-f were depicted in Scheme 1 as path A and path B, respectively. In path A, compounds 8a-d was obtained by coupling of bromide 7a-b with the appropriated amino-acid under Ullmann coupling reaction conditions. Then, compounds 8a-d were directly subjected to esterication without further purication to afford compounds 9a-d under conditions of K 2 CO 3 and CH 3 I. Finally, compounds 13a-f were obtained through the reaction between 9a-d and 10a-b.
In path B, the starting material 11a-b were provided from corresponding benzaldehyde according the reported procedure.
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Compounds 12a-d, then, were prepared under Strecker reaction conditions using compounds 11a-b, TMSCN and corresponding ketone as substrates. Finally, compounds 13g-j were obtained by reacting 12a-d with 10b. Other analogues, 14a-d and 15a-i, were synthesized form 13a-b by substitution, alkylation, oxidation, or hydrolysis reaction as shown in Scheme 2.
Biology activity
The in vitro anti-proliferation activities were evaluated by using LNCaP/AR cells (prostate cancer cells overexpressing AR). In order to mimic the CRPC state, the cells were cultured in charcoal stripped serum and treated with compounds for 6 days. The results were summarized in Tables 1, 2 and 3. The hydroxyl triuoroethyl analog compound 13a, was rst prepared because of its easily synthesis, showed 0.38 mM activity against LNCaP-AR cells compared with ENT of 0.25 mM. Encourage by this result, C-ring analogs of cyclobutyl 13c and cyclohexyl 13g were also prepared and achieved sub-mM activity. However, to our surprise, the closest isostere of amide, Nmethylamino triuoroethyl analog 14a lost the activity by 10-fold. Considering the poor solubility of ENT, more hydroxyl groups were introduced. To our delight, compounds 14b, 14c and 14d were also expressed good activity with IC 50 from 0.35 to 0.92 mM.
Analogues with unsubstituted aromatic A-ring were also prepared in order to further study SAR (Table 2) . Compound 13b represented an approximate 2-fold improvement over ENT. The second most active compound is 15b, with N-CH 3 triuoroethyl substitutions. Compound 15e with dihydroxyl propyl amino substitution provided 1.51 mM activity against LNCaP-AR. Other compounds 15a-d, 15h-i were found to have moderate to potent activities in the range of 0.15-0.83 mM against LNCaP-AR cell line.
ARN-509, which has substituted pyridine as B-ring and cyclobutyl as C-ring is under phase III trial for CRPC, 16 therefore modication of A-ring substitution and C-ring size were also conducted in this studies (Table 3) . However, in comparison with compound 13b, expanded the ring size of C-ring (compounds 13d and 13h-j) was detrimental to the activity. When C-ring was cyclobutyl group and B-ring is pyridine, compound 13e regained activity with IC 50 of 0.26 mM. To our (Fig. 3) showed that compound 13b inhibited the expression of PSA even at very low doses (2.5 mM) and the inhibition activity was dose-dependent. Interestingly, the result also showed that expression of AR was down-regulated, further investigation is needed to probe the mechanism.
The in vivo anti-tumor activity of 13b was evaluated using the CPRC (LNCaP-AR) xenogra model. SCID mice were castrated and subcutaneously inoculated with LNCaP-AR cells. When the tumor volumes reached 100-200 mm 3 , the mice were randomly grouped (8 animals each group) and oral administrated with compound 13b at 15 mg per kg q.d, 15 mg per kg q.3d, 5 mg per kg q.3d, and for ENT at 15 mg per kg q.d for 27 days. The tumor volumes and weight were measured every 3 days (Fig. 4) . Compound 13b at all dose levels inhibited the tumor proliferation compared with the control. 5 mg per kg q.3d of compound 13b have a moderate activity. 15 mg per kg q.d has similar inhibition compared ENT. The tumor inhibition rate of 13b at dose of 5 mg per kg q.3d, 15 mg per kg q.3d, 15 mg per kg q.d were 58.9%, 66.0%, 96.9%, respectively, whereas, the ENT was more than 100% (Fig. 4a) . In addition, the weight change 13b, ENT treated group and control group were slightly decreased (Fig. 4b) .
Conclusions
In summary, we have synthesized a series of thiohydantoin analogues bearing substituted 2,2,2-triuoro-1-phenylethanyl moiety. Compound 13b showed good cell activity against CRPC LNCaP-AR cell. Western blot analysis also veried compound 13b inhibited the expression of PSA in LNCaP-AR cells. Further evaluation in xenogra CRPC model showed compound 13b has anti-tumor activity of 96.9% inhibition at 15 mg per kg q.d. Further optimization and relevant works are in progress. 
coupling constant J (Hz), assignment). ESI-HRMS spectra were recorded on a commercial apparatus and methanol was used to dissolve the sample. Reagents were purchased from commercial sources and were used as received unless mentioned otherwise.
Reactions were monitored by thin layer chromatography using silica gel GF 254 plates. Column chromatography was performed on silica gel (300-400 mesh).
Experimental section
Compounds 9, 12, 13 were prepared by using a slightly modied literature-known procedure.
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General procedure for the synthesis of 9. 7 (1.0 mmol), amino-acid (1.2 mmol), 10% CuI (0.1 mmol), 2% Cu (0.02 mol), 20% N,N-dimethylglycine (0.2 mmol) and K 2 CO 3 (2.0 mmol) in DMF (15.0 mL) was stirred at 80 C for 24 h, under the protection of nitrogen. Aer the reaction, 1 N HCl was added to adjust the PH value to 3-4. Then, the solution was partitioned between ethyl acetate and water. The organic layer was concentrated to give the crude product for the owing reaction. A stirred solution of the crude product and K 2 CO 3 (1.0 mmol) in DMF (5 mL) then, CH 3 I (1 mmol) was added. Aer the reaction, the solution was quenched with water (25 mL). Then, aqueous residue was extracted with EA (20 mL Â 3), dried over Na 2 SO 4 , concentrated and puried by column chromatography (PE : EA/1 : 3) to given compounds 9 (yield from 59-76%).
General procedure for the synthesis of 12. The mixture of 11 (1.0 mmol), TMSCN (2.0 mmol), ketone (4.0 mmol) and 5 mL AcOH was stirred in a sealed tube at 80 C for 24 h. The solution was neutralized with aqueous sodium hydrogen carbonate. Then, the mixture was extracted with ethyl acetate (20 mL Â 3). The combined organics were dried over Na 2 SO 4 , ltered, concentrated and puried by column chromatography (PE : EA/ 1 : 2) to give 12 (yield from 58-75%).
General procedure for the synthesis of 13a-f. To the mixture of compound 9a (53 mg, 0.17 mmol) and compound 10b (79 mg 0.34 mmol) in DMAc (10 mL), the mixture was heated to 80 C for 24 h. Aer the reaction, water (30 mL) was added. The resulting mixture was extracted with ethyl acetate, washed with brine, dried over sodium sulfate, concentrated and puried by column chromatography (PE : EA/1 : 1) to give a brown solid as crude product, which was puried by preparative chromatography to give compound 13a as a white solid (32 mg, 37% yield).
Compounds 13b-f were synthesized by a similar procedure as described for compound 13a. General procedure for the synthesis of 13g-j. To the mixture of compound 12a (54 mg, 0.17 mmol) and compound 10b (79 mg, 0.34 mmol) in DMAc (10 mL), the mixture was heated to 80 C for 24 h, and then MeOH (2 mL) and 1 N HCl (1 mL) added in the mixture. The reaction mixture was stirred at 90 C for 2 h.
Aer completion of the reaction (TLC), water (30 mL) were added. The resulting mixture was extracted with ethyl acetate, washed with brine, dried over sodium sulfate, concentrated and puried by column chromatography (PE : EA/1 : 1) to give a brown solid as crude product, which was puried by preparative chromatography to give compound 13g as a white solid (26 mg, 28% yield).
Compounds 13h-j were synthesized by a similar procedure as described for compound 13g. , 1H), 3.28-2.83 (m, 1H), 2.19-2.00 (m, 4H) The reaction was stirred at room temperature for 30 min, and concentrated under vacuum to give the crude product for the owing reaction. A stirred solution of the crude product and aqueous ammonia in THF was reuxed overnight, and concentrated under vacuum to give the crude product. Puri-cation by ash chromatography afforded the products 14a (410 mg, 79% yield). Compounds 14b-d and 15b-e were synthesized by a similar procedure as described for compound 14a. 
4-(4-Oxo-2-thioxo-1-(4-(2,2,2-triuoro-1-hydroxyethyl)phenyl)-1,3-diazaspiro[4.4]nonan-3-yl)-2-(triuoromethyl)benzonitrile (13h
1.7 Hz, 1H), 7.67 (d, J ¼ 8.2 Hz, 2H), 7.31 (t, J ¼ 9.3 Hz, 2H), 5.12 (q, J ¼ 6.6 Hz4-(3-(3-Fluoro-4-(2,2,2-triuoro-1-(methylamino)ethyl)phenyl)- 4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(triuoromethyl) ben-zonitrile (14a4-(3-(4-(1-((2,3-Dihydroxypropyl)amino)-2,2,2-triuoroethyl)-3- uorophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2- (triuoromethyl)benzonitrile (14d
4-(4,4-
In a 20 mL tube sealing, 13b (49 mg, 0.1 mmol), concentrated H 2 SO 4 (5 mL), were added. The mixture was sealed and stirred for 24 h at 100 C. Aer the reaction, the mixture was poured into 100 mL ice water and saturated sodium bicarbonate was added to adjust pH to 4. The mixture was washed with EA (30 mL Â 3) and the organic layer was separated and dried over Na 2 SO 4 . Aer ltration and evaporation, the resulting crude product was puried by column chromatography with petrol ether as eluent to afford 15f (43 mg, 84% yield 
In a 25 mL round-bottomed ask, 13b (49 mg, 0.1 mmol), DMF (5 mL), and NaH 60% (12 mg, 0.3 mmol) were added. The mixture was stirred and simultaneously CH 3 I (12.3 mg 0.3 mmol) was added then, the reaction was stirred for 2 h at room temperature. Aer the reaction, 20 mL saturated NH 4 Cl was added, the mixtures was extracted with ethyl acetate. The organic layer was separated and dried over Na 2 SO 4 . Aer ltration and evaporation, the resulting crude product was puried by column chromatography with petrol ether as eluent to afford 15h (40 mg, 77% yield). 1 4-(4,4-Dimethyl-5-oxo-2-thioxo-3-(4-(2,2,2-triuoroacetyl)phenyl) imidazolidin-1-yl)-2-(triuoromethyl)benzonitrile (15i). In a 25 mL round-bottomed ask, 13b (49 mg, 0.1 mmol), DMSO (5 mL), and IBX (84 mg, 0.3 mmol) were added. The mixture was stirred for 12 h at room temperature. Aer the reaction, the mixture was poured over and ltered through a silica gel pad under vacuum the ltrate was added with EA (15 mL) and washed with water (20 mL Â 3) and saturated brine (15 mL Â 3). The organic layer was separated and dried over Na 2 SO 4 . Aer ltration and evaporation, the resulting crude product was puried by column chromatography with petrol ether as eluent to afford 15i (45 mg, 90% yield). 
Cell proliferation inhibition assay
Cell viability was determined using the CCK8 assay method. The cells were seeded in a 96-well plate at 3 Â 10 3 cells per well for 24 hours (37 C, 5% CO 2 ), and an equal volume of medium containing increasing concentration of inhibitors was added to each well. Aer a 5 days incubation, CCK8 reagent was added for 1.5 hours. The light absorption (OD) of the 96-well plate was measured at 490 nm using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices). All experiments were performed in triplicate. The percentage of viable cells was calculated and compared with that of the control cells, the half maximal inhibitory concentration (IC 50 ) was calculated by GraphPad Prism5 soware.
Western blot analysis
Cells were treated with a series of concentrations of 13b and ENT for 5 days at 37 C, then the cells were harvested, washed in ice-cold PBS, analyzed with RIPA buffer (10 mM Tris-HCl (pH 7.8), 1% NP40, 0.15 M NaCl, 1 mM EDTA, 10 mM aprotinin, 1 mM NaF and 1 mM Na 3 VO 4 ), protease inhibitors, phosphatase cocktails A and B, and PMSF (1 mM). Protein concentration was determined by the BCA Protein Assay Kit (beyotime#p0012s), the sample proteins were separated by 10% SDS-PAGE gel and transferred onto 0.2 um polyvinylidene diuoride membranes (millpore#ISEQ00010), then incubated overnight at 4 C with the AR or PSA antibody overnight at the indicated concentrations in 5% BSA/TBST buffer with gently shaking, then washing with 1 Â TBS/T 3 times and followed by incubation for 1.5 hour with a 1/5000 dilution of secondary HRP antibody in 5% nonfat milk/TBST. The target blots were detected with a chemiluminescence system.
In vivo model
The animal studies were carried out under protocols approved by the animal protection law of the People's Republic of China Care and Use Committees. All rodent studies were also carried out in accordance with the guidelines of Institutional Animal Care and Treatment Committee of Sichuan University in China. The male CB17 SCID mice were purchased (Beijing HFK Bioscience Co. ltd., Beijing, China). LNCap-AR cells were harvested during the exponential-growth phase, washed twice with serum-free medium, and re-suspended at a concentration of 1 Â 10 7 mL À1 . One hundred microliters of the cell suspension was injected subcutaneously into the hind ank of each male CB17 SCID mouse (6-7 weeks old) aer castrated 2 days. The tumors were allowed to grow to 100-150 mm 3 , at which point the mice were randomized into 5 groups (8 mice for each group). The mice were dosed orally with 13b (15 mg per kg q. 
